Bevacizumab as front-line treatment for newly diagnosed epithelial cancer

Reference

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA. Cancer J. Clin. 62(1), 10–29 (2012).
   PubMed Web of Science ®Google Scholar
• du Bois A, Rochon J, Pfisterer J, Hoskins WJ. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol. Oncol. 112(2), 422–436 (2009).
   PubMed Web of Science ®Google Scholar
• du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized Phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115(6), 1234–1244 (2009).
   PubMed Web of Science ®Google Scholar
• du Bois A, Quinn M, Thigpen T et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann. Oncol. 16(Suppl. 8), viii7–viii12 (2005).
   PubMed Web of Science ®Google Scholar
• Stuart GC, Kitchener H, Bacon M et al.; participants of 4th Ovarian Cancer Consensus Conference (OCCC); Gynecologic Cancer Intergroup. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int. J. Gynecol. Cancer 21(4), 750–755 (2011).
   PubMed Web of Science ®Google Scholar
• Vasey PA, Jayson GC, Gordon A et al.; Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 96(22), 1682–1691 (2004).
   PubMed Web of Science ®Google Scholar
• Pignata S, Scambia G, Ferrandina G et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized Phase III trial. J. Clin. Oncol. 29(27), 3628–3635 (2011).
   PubMed Web of Science ®Google Scholar
• Bookman MA. The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer. Ann. Oncol. 21(Suppl. 7), vii211–217 (2010).
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L et al.; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354(1), 34–43 (2006).
   PubMed Web of Science ®Google Scholar
• González Martín A. Intraperitoneal chemotherapy for optimally debulked advanced ovarian cancer: a new standard in patient care? Clin. Transl. Oncol. 9(7), 409–411 (2007).
   PubMed Web of Science ®Google Scholar
• Katsumata N, Yasuda M, Takahashi F et al.; Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a Phase 3, open-label, randomised controlled trial. Lancet 374(9698), 1331–1338 (2009).
   PubMed Web of Science ®Google Scholar
• Noriyuki K, Makoto Y, Seiji I et al. Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. J. Clin. Oncol. 30, Abstract 5003 (2012).
   Google Scholar
• Kerbel RS. Tumor angiogenesis. N. Engl. J. Med. 358(19), 2039–2049 (2008).
   PubMed Web of Science ®Google Scholar
• Hefler LA, Zeillinger R, Grimm C et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol. Oncol. 103(2), 512–517 (2006).
   PubMed Web of Science ®Google Scholar
• Siddiqui GK, Elmasry K, Wong Te Fong AC et al. Prognostic significance of intratumoral vascular endothelial growth factor as a marker of tumour angiogenesis in epithelial ovarian cancer. Eur. J. Gynaecol. Oncol. 31(2), 156–159 (2010).
   PubMed Web of Science ®Google Scholar
• Mendiola M, Barriuso J, Redondo A et al. Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma. PLoS ONE 3(12), e4051 (2008).
   PubMed Web of Science ®Google Scholar
• Bentink S, Haibe-Kains B, Risch T et al. Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS ONE 7(2), e30269 (2012).
   PubMed Web of Science ®Google Scholar
• Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25(33), 5165–5171 (2007).
   PubMed Web of Science ®Google Scholar
• Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 25(33), 5180–5186 (2007).
   PubMed Web of Science ®Google Scholar
• Simpkins F, Belinson JL, Rose PG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol. Oncol. 107(1), 118–123 (2007).
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Felix H, Béatrice W et al. AURELIA: a randomized Phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J. Clin. Oncol. 30, Abstract LBA5002 (2012).
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA et al.; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365(26), 2473–2483 (2011).
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J et al.; ICON7 Investigators. A Phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365(26), 2484–2496 (2011).
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank SV, Goff BA et al. OCEANS: a randomized, double-blind, placebo-controlled Phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 30(17), 2039–2045 (2012).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Martin A, Gladieff L, Tholander B et al. Safety of front-line bevacizumab (BEV) combined with weekly paclitaxel (wPAC) and q3w carboplatin (C) for ovarian cancer (OC): results from OCTAVIA. J. Clin. Oncol. 30, Abstract 5017 (2012).
   PubMed Web of Science ®Google Scholar
• Konner JA, Grabon DM, Gerst SR et al. Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. J. Clin. Oncol. 29(35), 4662–4668 (2011).
   PubMed Web of Science ®Google Scholar